PBE

Invesco Dynamic Biotechnology & Genome ETF

Up$48.72
+$1.08
(+2.27%)
As of 2:30:31 PM EDT | 10/15/19  |  Market Open

PBE Trading Data

Open

$47.94

Low Price

$47.94

High Price

$48.78

Previous Last Price

$47.64

Bid Size

$48.67 X 500

Ask Size

$48.75 X 300

PBE Portfolio Data

AUM

$209,484,000

Shares

4,400

PE Ratio

55.84

Price / Book Ratio

4.85

Expense Ratio

0.59

Net Asset Value

$47.61

Volume

Volume

3,907

Avg. Volume (YDT)

16,977

Dollar Volume

$176,434

Weekly Avg. Volume

10,521

Monthly Avg. Volume

8,570

Quarterly Avg. Volume

8,934

PBE Fund Description

The Invesco Dynamic Biotechnology and Genome ETF is based on the Dynamic Biotech and Genome Intellidex Index. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

PBE Chart

PBE Summary

Fund Family

Invesco

Tracks This Index

Invesco Dynamic Biotechnology & Genome ETF

Inception Date

2005-06-23

Asset Class

Equity

Asset Class Size

Biotech

PBE Classification

Region (General)

North America

Region (Specific)

US

Sector

Health Care

Equity Index

Leveraged Family

PBE Holdings

Top 10 Holdings

Celgene Corp (CELG)
5.45%
Biogen Inc (BIIB)
5.33%
Gilead Sciences Inc (GILD)
5.28%
Amgen Inc (AMGN)
5.1%
Vertex Pharmaceuticals Inc (VRTX)
5.07%
Incyte Corp (INCY)
4.86%
Neurocrine Biosciences Inc (NBIX)
4.85%
Alexion Pharmaceuticals Inc (ALXN)
4.65%
Myriad Genetics Inc (MYGN)
3.63%
Emergent BioSolutions Inc (EBS)
3.56%

Total PBE Holdings

Total Holdings: 31

Celgene Corp (CELG)
5.45%
Biogen Inc (BIIB)
5.33%
Gilead Sciences Inc (GILD)
5.28%
Amgen Inc (AMGN)
5.1%
Vertex Pharmaceuticals Inc (VRTX)
5.07%
Incyte Corp (INCY)
4.86%
Neurocrine Biosciences Inc (NBIX)
4.85%
Alexion Pharmaceuticals Inc (ALXN)
4.65%
Myriad Genetics Inc (MYGN)
3.63%
Emergent BioSolutions Inc (EBS)
3.56%
Natera Inc (NTRA)
3.25%
United Therapeutics Corp (UTHR)
2.84%
Nektar Therapeutics (NKTR)
2.82%
Halozyme Therapeutics Inc (HALO)
2.8%
Ironwood Pharmaceuticals Inc (IRWD)
2.71%
Veracyte Inc (VCYT)
2.68%
Arrowhead Pharmaceuticals Inc (ARWR)
2.68%
Radius Health Inc (RDUS)
2.66%
Xencor Inc (XNCR)
2.66%
Portola Pharmaceuticals Inc (PTLA)
2.63%
Genomic Health Inc (GHDX)
2.62%
Vanda Pharmaceuticals Inc (VNDA)
2.59%
Arena Pharmaceuticals Inc (ARNA)
2.51%
Alkermes PLC (ALKS)
2.46%
Exelixis Inc (EXEL)
2.43%
Coherus Biosciences Inc (CHRS)
2.43%
Repligen Corp (RGEN)
2.39%
Enanta Pharmaceuticals Inc (ENTA)
2.38%
Voyager Therapeutics Inc (VYGR)
2.36%
FibroGen Inc (FGEN)
2.34%
PowerShares Dynamic Biotechnology & Genome Portfolio ETF (PBE)
0%

PBE Technicals

Alpha

-2.32

Beta

1.46

Leverage

Long

Standard Deviation

2.7

PBE Dividends

Dividend Date

2018-09-24

Latest Dividend

0.002

Annual Dividend

0

Annual Dividend Rate

0

Annual Dividend Yield

1.0E-5

PBE Performance

YTD Return

3.51%

1 Year Return

-8.64%

3 Year Return

22.66%

5 Year Return

-2.36%

10 Year Return

211.37%

PBE Related Articles

© 2019 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.